Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand

Overview

• Biotech firm's Q3 product revenue rose 30% yr/yr, driven by VYJUVEK sales growth

• Q3 net income declined yr/yr despite higher revenue, reflecting increased costs and tax expense

• Company authorized $400 mln share repurchase program

Outlook

• Krystal Biotech expects to launch VYJUVEK in Italy in early 2027

• Company sees FY 2026 non-GAAP R&D and SG&A expenses of $155 mln to $165 mln

• Company expects interim results for KB111 study before year end

Result Drivers

• VYJUVEK DEMAND - Co said patient demand for VYJUVEK in the US continues to grow, with over 760 reimbursement approvals and expanding prescriber base

• INTERNATIONAL EXPANSION - Co said expansion in Germany, France, and Japan is broadening VYJUVEK prescriber base and converting physician interest into patient starts

• PRICING PROGRESS - Co completed pricing negotiations in Germany and Italy, expects Italy launch in early 2027

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Krystal Biotech, Inc. is $400.00, about 20.4% above its October 30 closing price of $332.29

• The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 40 three months ago

Reuters Recommended Reads

• Oct 30 - Sanofi teases appetite for larger deals, lifts 2026 growth targets under new CEO Garijo

• Oct 30 - US health department to remove broad black box warning from three estrogen patch products

• Oct 30 - AstraZeneca CEO strikes bullish tone on pipeline as stock rallies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)